Areteia Therapeutics

Areteia Therapeutics company information, Employees & Contact Information

Updated June 2026

Quick answer

Areteia Therapeutics is a Biotechnology Research company and founded in 2022. It has approximately 32 employees on record. Contact data was last refreshed in June 2026. Find Areteia Therapeutics's verified employee emails, phone numbers, headquarters address, and key decision makers below.

Areteia Therapeutics is a new biotechnology company committed to putting asthma patients in better control of their disease—and back in control of their lives—with the first potential oral drug for eosinophilic asthma.

Company Details

Employees
32
Founded
2022
Address
Research Triangle Park, North Carolina, Us
Industry
Biotechnology Research
NAICS
Research and Development in Biotechnology (except Nanobiotechnology)
HQ
Research Triangle Park, North Carolina
Looking for a particular Areteia Therapeutics employee's phone or email?

Areteia Therapeutics Questions

News

Areteia Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference on Tuesday January 14, 2025 - Business Wire

Areteia Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference on Tuesday January 14, 2025 Business Wire

Knopp Biosciences and Population Health Partners Create Areteia Therapeutics, New Clinical-Stage Asthma Company, with $350 Million in Funding - Bain Capital

Knopp Biosciences and Population Health Partners Create Areteia Therapeutics, New Clinical-Stage Asthma Company, with $350 Million in Funding Bain Capital

Areteia Therapeutics Announces Positive Topline Results from the First Phase III Study of Oral Dexpramipexole in Eosinophilic Asthma - Yahoo Finance

Areteia Therapeutics Announces Positive Topline Results from the First Phase III Study of Oral Dexpramipexole in Eosinophilic Asthma Yahoo Finance

Areteia Therapeutics Announces Additional $75MM in Series A Financing for Oral Dexpramipexole in Eosinophilic Asthma - Business Wire

Areteia Therapeutics Announces Additional $75MM in Series A Financing for Oral Dexpramipexole in Eosinophilic Asthma Business Wire

Areteia Therapeutics Announces Appointments of Donald J. Hayden, Jr. and Ian F. Smith to Its Board of Directors - Business Wire

Areteia Therapeutics Announces Appointments of Donald J. Hayden, Jr. and Ian F. Smith to Its Board of Directors Business Wire

Areteia Therapeutics Announces Appointment of Daniel Becker, M.D., Ph.D. To Board of Directors - Business Wire

Areteia Therapeutics Announces Appointment of Daniel Becker, M.D., Ph.D. To Board of Directors Business Wire

Areteia Therapeutics Announces Start of Phase III Clinical Trials of Oral Dexpramipexole in Eosinophilic Asthma - Business Wire

Areteia Therapeutics Announces Start of Phase III Clinical Trials of Oral Dexpramipexole in Eosinophilic Asthma Business Wire

Top Areteia Therapeutics Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant